Advertisement

Topics

Getting Ready for Resistance to First-Gen NTRK Inhibitors

10:33 EDT 8 Apr 2019 | Medscape

Just a few months ago, larotrectinib was approved for treating any NTRK+ tumor. Already, there are studies in place to address any mutations that emerge with the first-generation TRK-targeted agent.
Medscape Medical News

Original Article: Getting Ready for Resistance to First-Gen NTRK Inhibitors

NEXT ARTICLE

More From BioPortfolio on "Getting Ready for Resistance to First-Gen NTRK Inhibitors"

Advertisement
Quick Search
Advertisement
Advertisement